Status: current, Primitive. Date: 31-Jul 2020. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3880787013 | Crizanlizumab (substance) | en | Fully specified name | Active | Case insensitive | SNOMED CT core |
| 3880788015 | Crizanlizumab | en | Synonym | Active | Case insensitive | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Crizanlizumab | Has disposition | Selective adhesion molecule inhibitor | true | Inferred relationship | Some | ||
| Crizanlizumab | Is a | Selective adhesion molecule inhibitor | true | Inferred relationship | Some | ||
| Crizanlizumab | Is a | Monoclonal IgG | true | Inferred relationship | Some | ||
| Crizanlizumab | Has disposition | Immunomodulator | true | Inferred relationship | Some | ||
| Crizanlizumab | Is a | Murine-human monoclonal IgG antibody | false | Inferred relationship | Some | ||
| Crizanlizumab | Is a | Immunosuppressant | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Crizanlizumab only product | Has active ingredient | True | Crizanlizumab | Inferred relationship | Some | 1 |
| Crizanlizumab only product in parenteral dose form | Has active ingredient | True | Crizanlizumab | Inferred relationship | Some | 1 |
| Crizanlizumab-containing product in parenteral dose form | Has active ingredient | True | Crizanlizumab | Inferred relationship | Some | 1 |
| Crizanlizumab-containing product | Has active ingredient | True | Crizanlizumab | Inferred relationship | Some | 1 |
Reference Sets
Substance foundation reference set
FHIR